Gene Profiling Uncovers Actionable Mutations in More Than Half of Non-Small Cell Lung Cancers

NEW YORK (GenomeWeb) – Targeted sequencing matched mutations to therapeutic options in more than half of the non-small cell lung cancer patients analyzed in a new study.

NSCLC accounts for 85 percent to 90 percent of the approximately 222,500 new lung cancer cases in the US each year. Recent studies have uncovered a number of genes that are frequently mutated in NSCLC and guidelines from the National Comprehensive Cancer Network (NCCN) recommend testing for seven genes in NSCLC patients to match them to targeted therapies.